Abelacimab

From Food & Medicine Encyclopedia


Synonyms[edit]

Abelacimab , ABELACIMAB, MAA 868, MAA-868, MAA868

Thesaurus

A human anti-factor XI (FXI) monoclonal antibody, with potential anti-thrombotic activity. Upon administration, abelacimab targets and binds to the catalytic domain of FXI, thereby inactivating FXI, and also inhibits the activated form of FXI factor XIa. This prevents the activation of factor XIIa (FXIIa). The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization., Amino Acid, Peptide, or Protein, Pharmacologic Substance

  • NCI Thesaurus (external)

C20401. This concise article on Abelacimab incorporates public domain text from the US National Library of Medicine.


This article is a stub.

You can help WikiMD by registering to expand it.
Editing is available only to registered and verified users.
WikiMD is a comprehensive, free health & wellness encyclopedia.


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.